TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Arm Exercise Capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arm Function/Endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: aRap1b assay reproducibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance of restoration adaptation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence or absence of caries
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance of marginal adaptation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of VIA and VIA/VILI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glucagon levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline in general well-being
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Concentration of volatile organic compounds in exhaled air at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parameters of single-lead ECG and pulse wave
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: C-Reactive Protein (CRP) Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short-Chain Fatty Acids (SCFA) Levels in Stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of egg consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nutritional outcomes
Primary endpoint: Intraperative blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Safety of B7H3-IL7Ra CAR T cells infusion
Endpoint domain: Adverse events/effects
Primary endpoint: Nicotine addiction level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of active clinic patients who accepted enrollment and completed the study protocol
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Muscle mass measurement using calf circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle mass measurement using X-ray absorptiometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of patients with vitamin D adequacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: VDBP level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of participants with treatment-related serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Substrate-specific JVO2 of ventricular myocardial mitochondrial oxidative capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Peripheral inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance comparison to RT-PCR assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pattern of admission of children with covid-19
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalization of Surface EMG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bisoprolol peak level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood pressure evolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: time in 70 - 180 mg/dL glycemic range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of subjects with mRS score 0-2 on day 90
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Pain perception
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Mean plasma residual concentration of venetoclax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: first occurrence of major adverse cardiovascular events (MACE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Symptom evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: One stage stone free rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Qualitative agreement between tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to Antenatal Supplement Intervention (pill count)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Adherence to Antenatal Supplement Intervention (self report)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pattern of metabolic diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Completion Rate
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Accuracy of microcirculation assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical Activity Barriers and Facilitators
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Delay between sympathetic discharge and rhythmic event
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in level of Depression (DASS-21)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in level of Anxiety (DASS-21)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in Physical Function (PROMIS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: IOP reduction of > 20% from Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of ESTAIR Manual
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acceptability of ESTAIR Manual
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Feasibility of ITI-Cultural Module
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acceptability of ITI-Cultural Module
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Progression of disease within 24 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Imaging changes during transition from asymptomatic to symptomatic AD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensitivity and specificity of 89Zr-girentuximab PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of advanced colorectal adenoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Amplitude of sensory-evoked hemodynamic responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Peak response rate during extinction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Demand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC0-last) of vamifeport
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC0-infinity) of vamifeport
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed concentration (Cmax) of vamifeport
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CAR19-tTregs efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Epilepsy Self-Management Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: rate of new ischemic stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: r-ACQ
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pressure of the cuff inflated with the loss-of-resistance syringe technique
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of airway leak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days to asymptomatic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cough and sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Dyspnea rating scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Level of uNK cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antipigmenting assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Incidence of hyperprogression
Endpoint domain: Adverse events/effects
Primary endpoint: Diameter stenosis by AI-QCA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: PET-driven RFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: PET-driven stress MBF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ease and utility of intervention sessions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Causes of death in kidney transplant recipients
Endpoint domain: Mortality/survival
Primary endpoint: Score change of the New freezing of gait questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Patient BPSD
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Tolerability of the NEAAR medical food
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of phenytoin and Levetiracetam
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Fasting glucose/insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum tolerated dose per dose (MTD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in daily 24-hour I-NRS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline postural sway
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation between SLEDAI-2K and SLEDAI-P/LUPIN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tissue distribution of 89Zr-Anti-CLDN18.2 mAbs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic analysis of 89Zr-Anti-CLDN18.2 mAbs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dosimetry estimates of 89Zr-Anti-CLDN18.2 mAbs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Message-specific knowledge/recall accuracy
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in mothers' Event-related potentials (ERPs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in maternal mentalization
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in mothers' reflective functioning
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Intestinal barrier defects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Response to food antigens in IBS patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Adverse Events (AEs) by incidence and severity
Endpoint domain: Adverse events/effects
Primary endpoint: Clinically significant shifts from baseline in clinical laboratory parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Cognitive Composite Scale score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: radiographic ridge width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of epic dream disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of PSD within 180 days
Endpoint domain: Mortality/survival
Primary endpoint: Difference in systolic BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Difference in diastolic BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Image Signal to Noise Ratio (SNR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients converting to ER expressing breast cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Amplitude of evoked potentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Latency of evoked potentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Morphology of evoked potentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Intraoperative movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postprandial incorporation of dietary protein-derived amino acids in duodenal mucosal protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 100-day survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Time to and total number of Intravesical recurrences (IVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of patients reaching a 40% ulcer area reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent accuracy of recorded neuraxial attempts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of renal scarring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Endometrial compaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Osteotomy change measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change from baseline cognitive function in the Amnesia Light and Brief Assessment (ALBA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline cognitive function in the Assessment Battery of Cognition (ABACO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline cognitive function in Geriatric Depression Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cardiopulmonary Exercise Testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in breadth of thought and ruminations scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Anhedonia level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Average fasting glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Genital Hygiene Behavior Inventory (GHBI)
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Pharyngeal compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Chinese Handwriting Legibility Assessment for Children (CHLAC)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Changes in The Battery of Chinese Basic Literacy (BCBL)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Incidence of Adverse Event of Special Interest (AESI)
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitivity and specificity of lab tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of halitosis parameters (organoleptic scores)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall experience of the PPFR
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Resolution of pelvic somatic dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-efficacy to cope with economic abuse
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Self-efficacy to use family planning in the face of reproductive coercion
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Self-efficacy to seek formal intimate partner violence support services
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Self-efficacy to seek support from group members if experiencing violence
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Cancer worry level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Parameters of automated pupillometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Adverse Events Grade 3-5
Endpoint domain: Adverse events/effects
Primary endpoint: Histopathology analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of RNA biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of organ failures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: size of biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exergame Enjoyment Questionnaire (EEQ)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Early postoperative neurocognitive disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Intraoperative silent brain infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in plasma concentration of neurofilament light (NFL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in plasma concentration of phosphorylated tau (pTau-181)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Grade ≥2 Toxicity for GU
Endpoint domain: Adverse events/effects
Primary endpoint: Shoulder Range of Movement (ROM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life (Barthel Scale)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in disease activity (SLEDAI score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognition using the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sleep Quality in the MCI Participant using the Pittsburgh Sleep Quality Index (PSQI)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Caregiver Burden using the Zarit Burden Interview (ZBI)
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Skills and Difficulties Questionnaire (SDQ-Ita)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: MVIC ankle plantarflexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: MVIC ankle dorsiflexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: VFQ 25 score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Safety endpoints: adverse events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in abdominal obesity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduce systolic and diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improve health-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Scores of the verbal fluency test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Scores of the Rey auditory verbal learning test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in scores on the Montreal Cognitive Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in scores on the Columbia University Autobiographical Memory Interview short form
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in resting-state EEG peak frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circulating tumor deoxyribonucleic acid (ctDNA) status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Routine blood tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Nutritional knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to Pain Onset
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Localization of endotracheal tube placement by ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Localization of endotracheal tube placement by breath sounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Kinetic GFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Relative change in LDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes